- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02296125
AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)
A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Camperdown, Australia, 2050
- Research Site
-
Chermside, Australia, 4032
- Research Site
-
Clayton, Australia, 3168
- Research Site
-
Heidelberg, Australia, 3084
- Research Site
-
Kogarah, Australia, 2217
- Research Site
-
Nedlands, Australia, 6009
- Research Site
-
Woolloongabba, Australia, 4102
- Research Site
-
-
-
-
-
Leuven, Belgium, 3000
- Research Site
-
Liège, Belgium, 4000
- Research Site
-
Roeselare, Belgium, 8800
- Research Site
-
-
-
-
-
Porto Alegre, Brazil, 90610-000
- Research Site
-
-
-
-
-
Sofia, Bulgaria, 1330
- Research Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Research Site
-
Ottawa, Ontario, Canada, K1H 8L6
- Research Site
-
Toronto, Ontario, Canada, M5G 2M9
- Research Site
-
Toronto, Ontario, Canada, M4N 3M5
- Research Site
-
Toronto, Ontario, Canada, M5G 1X5
- Research Site
-
-
-
-
-
Beijing, China, 100071
- Research Site
-
Beijing, China, 100853
- Research Site
-
Changchun, China, 130012
- Research Site
-
Changchun, China, 130021
- Research Site
-
Chongqing, China, 400038
- Research Site
-
Chongqing, China, 400042
- Research Site
-
Chongqing, China, 400037
- Research Site
-
Fuzhou, China, 350025
- Research Site
-
Guangzhou, China, 510080
- Research Site
-
Hangzhou, China, 310022
- Research Site
-
Nanjing, China, 210029
- Research Site
-
Nanning, China, 530021
- Research Site
-
Shanghai, China, 200433
- Research Site
-
Shenyang, China, 110001
- Research Site
-
Suzhou, China, 215006
- Research Site
-
Wuhan, China, 430071
- Research Site
-
Xi'an, China, 710061
- Research Site
-
Xi'an, China, 710038
- Research Site
-
Yangzhou, China, 225001
- Research Site
-
Ürümqi, China, 830000
- Research Site
-
-
-
-
-
Ostrava, Czechia, 708 52
- Research Site
-
-
-
-
-
Caen, France, F-14033
- Research Site
-
Creteil, France, 94010
- Research Site
-
Lyon Cedex 08, France, 69373
- Research Site
-
Nantes, France, 44202
- Research Site
-
Toulon Naval, France, 83800
- Research Site
-
Villejuif, France, 94805
- Research Site
-
-
-
-
-
Bad Berka, Germany, 99437
- Research Site
-
Berlin, Germany, 13125
- Research Site
-
Gauting, Germany, 82131
- Research Site
-
Halle, Germany, 06120
- Research Site
-
Heidelberg, Germany, 69126
- Research Site
-
Karlsruhe, Germany, 76137
- Research Site
-
Lübeck, Germany, 23538
- Research Site
-
München, Germany, 81925
- Research Site
-
Villingen-Schwenningen, Germany, 78052
- Research Site
-
-
-
-
-
Farkasgyepü, Hungary, 8582
- Research Site
-
Gyöngyös - Mátraháza, Hungary, 3200
- Research Site
-
Miskolc, Hungary, 3529
- Research Site
-
Székesfehérvár, Hungary, 8000
- Research Site
-
Tatabánya, Hungary, 2800
- Research Site
-
Zalaegerszeg, Hungary, 8900
- Research Site
-
-
-
-
-
Haifa, Israel, 31999
- Research Site
-
Kfar-Saba, Israel, 4428164
- Research Site
-
Petach Tikva, Israel, 49100
- Research Site
-
Tel Hashomer, Israel, 52621
- Research Site
-
-
-
-
-
Cremona, Italy, 26100
- Research Site
-
Lecce, Italy, 73100
- Research Site
-
Lecco, Italy, 23900
- Research Site
-
Orbassano, Italy, 10043
- Research Site
-
Parma, Italy, 43126
- Research Site
-
Roma, Italy, 00144
- Research Site
-
Sondrio, Italy, 23100
- Research Site
-
Terni, Italy, 05100
- Research Site
-
-
-
-
-
Chuo-ku, Japan, 104-0045
- Research Site
-
Fukuoka-shi, Japan, 812-8582
- Research Site
-
Hirakata-shi, Japan, 573-1191
- Research Site
-
Kanazawa-shi, Japan, 920-8641
- Research Site
-
Kashiwa, Japan, 277-8577
- Research Site
-
Kobe-shi, Japan, 650-0047
- Research Site
-
Matsuyama-shi, Japan, 791-0280
- Research Site
-
Natori-shi, Japan, 981-1293
- Research Site
-
Osaka-shi, Japan, 541-8567
- Research Site
-
Osakasayama-shi, Japan, 589-8511
- Research Site
-
Sagamihara-shi, Japan, 252-0375
- Research Site
-
Sakai-shi, Japan, 591-8555
- Research Site
-
Sendai-shi, Japan, 980-0873
- Research Site
-
Sunto-gun, Japan, 411-8777
- Research Site
-
Yokohama-shi, Japan, 241-8515
- Research Site
-
Yokohama-shi, Japan, 232-0024
- Research Site
-
Yokohama-shi, Japan, 240-8555
- Research Site
-
Yokohama-shi, Japan, 236-0051
- Research Site
-
-
-
-
-
Cheongju-si, Korea, Republic of, 28644
- Research Site
-
Incheon, Korea, Republic of, 405-760
- Research Site
-
Seongnam-si, Korea, Republic of, 13620
- Research Site
-
Seoul, Korea, Republic of, 03722
- Research Site
-
Seoul, Korea, Republic of, 02841
- Research Site
-
Seoul, Korea, Republic of, 06591
- Research Site
-
Seoul, Korea, Republic of, 5030
- Research Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 59100
- Research Site
-
Kuantan, Malaysia, 25100
- Research Site
-
Kuching, Malaysia, 93586
- Research Site
-
-
-
-
-
Cebu, Philippines, 6000
- Research Site
-
Manila, Philippines, 1000
- Research Site
-
Quezon City, Philippines, 1100
- Research Site
-
-
-
-
-
Brzozoów, Poland, 36-200
- Research Site
-
Otwock, Poland, 05-400
- Research Site
-
Poznań, Poland, 60-569
- Research Site
-
Szczecin, Poland, 70-891
- Research Site
-
Warszawa, Poland, 02-781
- Research Site
-
-
-
-
-
Amadora, Portugal, 2720-276
- Research Site
-
Lisboa, Portugal, 1769-001
- Research Site
-
Porto, Portugal, 4200-072
- Research Site
-
Vila Nova de Gaia, Portugal, 4434-502
- Research Site
-
-
-
-
-
Bucharest, Romania, 050098
- Research Site
-
Bucuresti, Romania, 022328
- Research Site
-
Craiova, Romania, 200347
- Research Site
-
-
-
-
-
Saint Petersburg, Russian Federation, 198255
- Research Site
-
Saint Petersburg, Russian Federation, 197022
- Research Site
-
Saint Petersburg, Russian Federation, 197758
- Research Site
-
-
-
-
-
Barcelona, Spain, 08041
- Research Site
-
Barcelona, Spain, 08907
- Research Site
-
Barcelona, Spain, 08221
- Research Site
-
Coruña, Spain, 15006
- Research Site
-
Lugo, Spain, 27003
- Research Site
-
Lérida, Spain, 25198
- Research Site
-
Madrid, Spain, 28040
- Research Site
-
Málaga, Spain, 29010
- Research Site
-
Sevilla, Spain, 41014
- Research Site
-
Zaragoza, Spain, 50009
- Research Site
-
-
-
-
-
Linköping, Sweden, 581 85
- Research Site
-
-
-
-
-
Luzern, Switzerland, 6000
- Research Site
-
Winterthur, Switzerland, 8401
- Research Site
-
Zürich, Switzerland, 8091
- Research Site
-
-
-
-
-
Kaohsiung, Taiwan, 833
- Research Site
-
Taichung City, Taiwan, 402
- Research Site
-
Tainan, Taiwan, 704
- Research Site
-
Tainan City, Taiwan, 73657
- Research Site
-
Taoyuan City, Taiwan, 333
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10330
- Research Site
-
Bangkok, Thailand, 10400
- Research Site
-
Bangkok, Thailand, 10700
- Research Site
-
Hat Yai, Thailand, 90110
- Research Site
-
Muang, Thailand, 50200
- Research Site
-
-
-
-
-
Ankara, Turkey, 6500
- Research Site
-
Istanbul, Turkey, 34069
- Research Site
-
Izmir, Turkey, 35100
- Research Site
-
-
-
-
-
Dnipro, Ukraine, 49102
- Research Site
-
Kryvyi Rih, Ukraine, 50048
- Research Site
-
Lviv, Ukraine, 79031
- Research Site
-
Sumy, Ukraine, 40022
- Research Site
-
-
-
-
-
London, United Kingdom, NW1 2BU
- Research Site
-
Maidstone, United Kingdom, ME16 9QQ
- Research Site
-
Withington, United Kingdom, M20 4BX
- Research Site
-
-
-
-
California
-
Anaheim, California, United States, 92801
- Research Site
-
Santa Rosa, California, United States, 95403
- Research Site
-
West Hills, California, United States, 91307
- Research Site
-
-
Florida
-
Tampa, Florida, United States, 33612
- Research Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Research Site
-
Atlanta, Georgia, United States, 30322
- Research Site
-
Marietta, Georgia, United States, 30060
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Research Site
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Research Site
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Research Site
-
-
North Carolina
-
Salisbury, North Carolina, United States, 28144
- Research Site
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- Research Site
-
-
-
-
-
Hanoi, Vietnam, 100000
- Research Site
-
Hanoi, Vietnam, 10000
- Research Site
-
Ho Chi Minh City, Vietnam, 70000
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, aged at least 18 years.
- Pathologically confirmed adenocarcinoma of the lung.
- Locally advanced or metastatic NSCLC, not amenable to curative surgery or radiotherapy.
- The tumour harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).
- Mandatory provision of an unstained, archived tumour tissue sample in a quantity sufficient to allow for central analysis of EGFR mutation status.
- Patients must be treatment-naïve for locally advanced or metastatic NSCLC and eligible to receive first-line treatment with gefitinib or erlotinib as selected by the participating centre. Prior adjuvant and neo-adjuvant therapy is permitted(chemotherapy, radiotherapy, investigational agents).
- Provision of informed consent prior to any study specific procedures, sampling, and analysis.
- World Health Organization Performance Status of 0 to 1 with no clinically significant deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks
Exclusion Criteria:
Treatment with any of the following:
- Prior treatment with any systemic anti-cancer therapy for locally advanced/metastatic NSCLC.
- Prior treatment with an EGFR-TKI.
- Major surgery within 4 weeks of the first dose of study drug.
- Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
- Patients currently receiving medications or herbal supplements known to be potent inducers of cytochrome P450 (CYP) 3A4.
- Alternative anti-cancer treatment
- Treatment with an investigational drug within five half-lives of the compound or any of its related material.
- Any concurrent and/or other active malignancy that has required treatment within 2 years of first dose of study drug.
- Spinal cord compression, symptomatic and unstable brain metastases, except for those patients who have completed definitive therapy, are not on steroids, have a stable neurologic status for at least 2 weeks after completion of the definitive therapy and steroids.
- Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of AZD9291.
Any of the following cardiac criteria:
- Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs, using the screening clinic ECG machine-derived QTcF value.
- Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.
- Any patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval.
- Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
- Involvement in the planning and/or conduct of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AZD9291+ placebo
AZD9291 (80 mg or 40 mg orally, once daily) plus placebo Erlotinib (150mg or 100mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily), in accordance with the randomization schedule.
|
The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances.
A cycle of treatment is defined as 21 days of once daily treatment.
Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Other Names:
The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced.
A cycle of treatment is defined as 21 days of once daily treatment.
Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Other Names:
|
Active Comparator: Standard of Care + placebo AZD9291
Erlotinib (150 mg or 100 mg orally, once daily) or placebo Gefitinib (250 mg orally, once daily) plus placebo AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomisation schedule. Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291). |
The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria. Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).
Other Names:
The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria. Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291).
Other Names:
The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances.
A cycle of treatment is defined as 21 days of once daily treatment.
Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Median Progression Free Survival (PFS) (Months)
Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression
|
Progression-free survival was defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression and was used to assess the efficacy of single agent osimertinib compared with SoC EGFR-TKI therapy as measured by PFS.
The primary endpoint of PFS was based on Investigator assessment.
|
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression
|
Percentage of Participants in Progression Free Survival at 6, 12, and 18 Months
Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression
|
Progression-free survival was defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from randomized therapy or received another anti-cancer therapy prior to progression and was used to assess the efficacy of single agent osimertinib compared with SoC EGFR-TKI therapy as measured by PFS.
|
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression
|
ORR was defined as the number (%) of participants with measurable disease with at least 1 visit response of Complete response (CR) or Partial response (PR) and it was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy.
ORR was based on Investigator assessment.
|
At baseline and every 6 weeks for the first 18 months and then every 12 weeks relative to randomisation until progression
|
Duration of Response (DoR)
Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression
|
Duration of response was defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy.
|
At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression
|
Disease Control Rate (DCR)
Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression
|
The DCR was defined as the percentage of participants who had a best overall response (BOR) of Complete response (CR), Partial response (PR) or Stable disease (SD) ≥6 weeks prior to any Progressive disease (PD) event and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy.
|
At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression
|
Depth of Response
Time Frame: At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression
|
The Depth of response was defined as the relative change in the sum of the longest diameters of Response Evaluation Criteria in Solid Tumors (RECIST) Target lesions (TLs) at the nadir, in the absence of new lesions (NLs) or progression of Non-target lesions (NTLs), compared to baseline and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy
|
At baseline and every 6 weeks for the first 18 months and then every 12 weeks until objective disease progression
|
Overall Survival (OS)- Number of Participants With an Event
Time Frame: From first dose to end of study or date of death from any cause, whichever comes first, assessed every 6 weeks (approximately 29 months)
|
Overall survival was defined as the time from the date of randomisation until death from any cause and was used to further assess the efficacy of osimertinib compared with SoC EGFR-TKI therapy
|
From first dose to end of study or date of death from any cause, whichever comes first, assessed every 6 weeks (approximately 29 months)
|
Plasma Concentrations of AZD9291
Time Frame: Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months)
|
To characterise the pharmacokinetics (PK) of osimertinib
|
Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months)
|
Plasma Concentrations of Metabolites AZ5104
Time Frame: Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months)
|
To characterise the pharmacokinetics (PK) of osimertinib metabolite AZ5104.
|
Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months)
|
Plasma Concentrations of Metabolite AZ7550
Time Frame: Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months)
|
To characterise the pharmacokinetics (PK) of osimertinib metabolite AZ7550.
|
Blood samples collected from each participant at pre-dose, 0.5 to 2 hours, and 3 to 5 hours post-dose on Day 1 Cycle 1, and every other cycle thereafter up to and including Cycle 13 (approximately 9 months)
|
Participants Reported Outcome by Cancer Therapy Satisfaction Questionnaire 16 Items (CTSQ-16 Questionnaire)
Time Frame: Questionnaire completed in cycle 2 and 3, prior to Week 6 scan (approximately 2 months)
|
The CTSQ-16 was a 16-item questionnaire measuring 3 domains related to participant's satisfaction with cancer therapy: Expectations of therapy, Feelings about side effects, and Satisfaction with therapy.
Scores ranged from 0 to 100 for each domain, with a higher score associated with the best outcome on each domain.
The three domains of interest were separately analysed using an ANCOVA stratified by race (Asian versus Non-Asian) and mutation type (Ex19del versus L858R).
The results of the analyses were presented in terms of mean together with standard deviation.
|
Questionnaire completed in cycle 2 and 3, prior to Week 6 scan (approximately 2 months)
|
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Questionnaires Lung Cancer 13 (QLQ-LC13)
Time Frame: Questionnaires completed at baseline, first 9 months, and at week 1, 2, 3, 4, 5, 6, 12, 18, 24, 30 and 36
|
The EORTC QLQ-LC13 was a lung-cancer-specific module comprising 13 questions to assess lung cancer symptoms (cough, haemoptysis, dyspnoea, and site-specific pain); treatment related side-effects (sore mouth, dysphagia, peripheral neuropathy, and alopecia); and pain medication.
An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items.
Higher scores on the global health status/QoL and functioning scales indicated better health status/QoL and function.
Higher scores on the symptoms scales indicated greater symptom burden.
The analysis was performed using a Mixed-effects model for repeated measures analysis on the change from baseline in PRO symptom score at each visit up to 9 months (281 days), including participants, treatment, visit and treatment by visit interaction as explanatory variables, the baseline PRO score as a covariate along with the baseline PRO score by visit interaction, using an unstructured covariance structure.
|
Questionnaires completed at baseline, first 9 months, and at week 1, 2, 3, 4, 5, 6, 12, 18, 24, 30 and 36
|
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 Items (EORTC QLQ-C30)
Time Frame: Questionnaires completed at baseline, first 9 months, and at week 6, 12, 18, 24, 30, and 36.
|
The EORTC QLQ-C30 cancer-specific questionnaire consisted of 30 questions, combined to produce 5 functional scales, 3 symptom scales, 6 individual items, and a global measure of health status/QoL.
An outcome variable consisting of a score from 0 to 100 was derived for each of the symptom scales/symptom items, the functional scales, and the global health status/QoL scale in the EORTC QLQ-C30.
Higher scores on the global health status and functioning scales indicated better health status/function.
Higher scores on the symptoms scales indicated greater symptom burden.
The analysis was performed using a Mixed-effects model for repeated measures analysis on the change from baseline in PRO symptom score at each visit up to 9 months (281 days), including participants, treatment, visit and treatment by visit interaction as explanatory variables, the baseline PRO score as a covariate along with the baseline PRO score by visit interaction, using an unstructured covariance structure.
|
Questionnaires completed at baseline, first 9 months, and at week 6, 12, 18, 24, 30, and 36.
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Walding A, Skaltsa K, Casamayor M, Ryden A. Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions. Qual Life Res. 2022 Aug;31(8):2535-2543. doi: 10.1007/s11136-022-03088-0. Epub 2022 Jan 31. Erratum In: Qual Life Res. 2022 Mar 24;:
- Cheng Y, He Y, Li W, Zhang HL, Zhou Q, Wang B, Liu C, Walding A, Saggese M, Huang X, Fan M, Wang J, Ramalingam SS. Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study. Target Oncol. 2021 Mar;16(2):165-176. doi: 10.1007/s11523-021-00794-6. Epub 2021 Feb 5.
- Leighl NB, Karaseva N, Nakagawa K, Cho BC, Gray JE, Hovey T, Walding A, Ryden A, Novello S. Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. Eur J Cancer. 2020 Jan;125:49-57. doi: 10.1016/j.ejca.2019.11.006. Epub 2019 Dec 12.
- Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
- Brown H, Vansteenkiste J, Nakagawa K, Cobo M, John T, Barker C, Kohlmann A, Todd A, Saggese M, Chmielecki J, Markovets A, Scott M, Ramalingam SS. Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. J Thorac Oncol. 2020 Jan;15(1):138-143. doi: 10.1016/j.jtho.2019.09.009. Epub 2019 Oct 9.
- Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden S, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam SS. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Nov 15;25(22):6644-6652. doi: 10.1158/1078-0432.CCR-19-1126. Epub 2019 Aug 22.
- Planchard D, Boyer MJ, Lee JS, Dechaphunkul A, Cheema PK, Takahashi T, Gray JE, Tiseo M, Ramalingam SS, Todd A, McKeown A, Rukazenkov Y, Ohe Y. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.
- Ohe Y, Imamura F, Nogami N, Okamoto I, Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, Vowler SL, Walding A, Nakagawa K. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol. 2019 Jan 1;49(1):29-36. doi: 10.1093/jjco/hyy179.
- Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Erlotinib Hydrochloride
- Gefitinib
- Osimertinib
Other Study ID Numbers
- D5160C00007
- 2014-002694-11 (EudraCT Number)
- U1111-1160-2242 (Other Grant/Funding Number: 112455)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
-
Allist Pharmaceuticals, Inc.UnknownLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung CancerChina
-
AstraZenecaParexelCompletedEGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerSpain, United States, Italy, Korea, Republic of, Malaysia
-
Shanghai JMT-Bio Inc.CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingLocally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
-
Xuanzhu Biopharmaceutical Co., Ltd.RecruitingLocally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Non-small Cell Lung CancerChina
-
PfizerRecruitingLocally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung CancerUnited States, China, Australia, Korea, Republic of, Japan
-
Shanghai JMT-Bio Inc.CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Not yet recruitingLocally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion MutationsChina
-
Centro de Tratamiento e Investigación sobre Cáncer...Not yet recruitingNon Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Exon 19 Deletion | EGFR G719X | EGFR Exon 21 MutationColombia
-
Blueprint Medicines CorporationTerminatedNeoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditionsUnited States
-
AstraZenecaTerminated
-
Shanghai JMT-Bio Inc.Active, not recruitingLocal Advanced or Metastatic NSCLC | Harboring EGFR Common MutationChina
Clinical Trials on AZD9291 80 mg/40 mg + placebo
-
AstraZenecaActive, not recruitingStage IB-IIIA Non-small Cell Lung CarcinomaUnited States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
-
Genencell Co. Ltd.Recruiting
-
Medicines for Malaria VentureQ-Pharm Pty Limited; Clinical Network Services (CNS) Pty Ltd; QIMR Berghofer...Completed
-
JW PharmaceuticalRecruitingGoutKorea, Republic of
-
AstraZenecaCompletedCarcinoma, Non-Small-Cell Lung With EGFR Mutation PositiveChina
-
Caliway Biopharmaceuticals Co., Ltd.Completed
-
Yuhan CorporationCompleted
-
GlaxoSmithKlineCompleted
-
UCB CelltechParexel; Comac Medical; MAC Clinical Research; ARENSIA, MoldovaCompletedPsoriatic ArthritisBulgaria, Moldova, Republic of, United Kingdom
-
AstraZenecaRecruitingStage II-IIIB Non-small Cell Lung CarcinomaSpain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore